Novo Nordisk’s first weight loss pill smashes sales forecasts as company hails surging
The maker of the fat-jab Wegovy hailed surging demand for its first weight-loss pill, after smashing sales forecasts.
Novo Nordisk launched its Wegovy pill in January as it fought back against Eli Lilly, the maker of rival drug Mounjaro, after seeing sales and profits tumble in the face of stiff competition.
The Danish pharmaceutical firm said yesterday that more than 2m prescriptions of the pill had been issued since its launch, with weekly prescriptions exceeding 200,000.
The firm said the Wegovy pill’s launch was the strongest of any obesity drug in the US. Sales of the pill reached £260million in the quarter to March 31, surpassing analyst predictions.
Overall revenue was also ahead of expectations at £8bn.
Miracle pill: Novo Nordisk launched its Wegovy pill in January as it fought back against Eli Lilly, the maker of rival drug Mounjaro, after seeing sales and profits tumble
DIY INVESTING PLATFORMS
AJ Bell
AJ Bell
Easy investing and ready-made portfolios
Hargreaves Lansdown
Hargreaves Lansdown
Free fund dealing and investment ideas
interactive investor
interactive investor
Flat-fee investing from £4.99 per month
Freetrade
Freetrade
Investing Isa now free on basic plan
Trading 212
Trading 212
Free share dealing and no account fee
Affiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence.